Seth Wander, MD, PhD

Seth Wander, MD, PhD, discusses the extended survival with elacestrant in a real-world, which was longer than the randomized phase 3 trial data.

Seth Wander, MD, PhD, discusses the tolerability of selective estrogen receptor degraders and next-generation anti-estrogen agents in breast cancer.

Seth Wander, MD, PhD, discusses genomic variations effect on elacestrant in ESR1-mutated breast cancer from findings in real-world data.

Seth Wander, MD, PhD, discusses approved and upcoming targeted therapies for patients with ESR1-mutated breast cancer.

Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.

Seth Wander, MD, PhD, discusses what research and topics excite him when looking to further evaluate future treatments for patients with breast cancer.